Palatin Technologies Inc (PTN)
2.00
-0.04
(-1.96%)
USD |
NYAM |
May 17, 16:00
2.02
+0.02
(+1.00%)
After-Hours: 20:00
Palatin Technologies Research and Development Expense (TTM): 25.13M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 25.13M |
| December 31, 2023 | 22.80M |
| September 30, 2023 | 21.62M |
| June 30, 2023 | 22.63M |
| March 31, 2023 | 22.66M |
| December 31, 2022 | 22.81M |
| September 30, 2022 | 23.87M |
| June 30, 2022 | 21.33M |
| March 31, 2022 | 17.37M |
| December 31, 2021 | 14.90M |
| September 30, 2021 | 13.49M |
| June 30, 2021 | 12.93M |
| March 31, 2021 | 13.38M |
| December 31, 2020 | 14.51M |
| September 30, 2020 | 13.76M |
| June 30, 2020 | 13.96M |
| March 31, 2020 | 14.36M |
| December 31, 2019 | 14.66M |
| September 30, 2019 | 14.36M |
| June 30, 2019 | 14.86M |
| March 31, 2019 | 15.82M |
| December 31, 2018 | 18.94M |
| September 30, 2018 | 22.03M |
| June 30, 2018 | 32.57M |
| March 31, 2018 | 44.54M |
| Date | Value |
|---|---|
| December 31, 2017 | 46.53M |
| September 30, 2017 | 48.62M |
| June 30, 2017 | 45.68M |
| March 31, 2017 | 38.95M |
| December 31, 2016 | 40.56M |
| September 30, 2016 | 43.70M |
| June 30, 2016 | 43.07M |
| March 31, 2016 | 42.32M |
| December 31, 2015 | 39.23M |
| September 30, 2015 | 32.23M |
| June 30, 2015 | 24.56M |
| March 31, 2015 | 17.38M |
| December 31, 2014 | 11.94M |
| September 30, 2014 | 10.30M |
| June 30, 2014 | 10.83M |
| March 31, 2014 | 11.03M |
| December 31, 2013 | 11.82M |
| September 30, 2013 | 11.63M |
| June 30, 2013 | 10.53M |
| March 31, 2013 | 11.86M |
| December 31, 2012 | 13.62M |
| September 30, 2012 | 13.87M |
| June 30, 2012 | 13.81M |
| March 31, 2012 | 12.90M |
| December 31, 2011 | 9.917M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
12.93M
Minimum
Jun 2021
25.13M
Maximum
Mar 2024
17.77M
Average
14.88M
Median
Research and Development Expense (TTM) Benchmarks
| Oragenics Inc | 15.49M |
| Outset Medical Inc | 56.15M |
| Perspective Therapeutics Inc | 24.91M |
| Ligand Pharmaceuticals Inc | 23.84M |
| Lumos Pharma Inc | 26.46M |